Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.61 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.40 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MASP2 | O00187 | 1/20 | 0.39 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642713 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL31715809 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2558585 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL32684929 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2552093 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL3503306 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL32684741 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2552092 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2989833 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA | |
| SCHEMBL2989831 | 1.00 | TSHR (0.61) | TSHRTP53EGLN1EGLN3PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011124227-A1 | BIOCIDAL ACID-ADJUSTED POLYMER WITH POLYPROPYLENE | VESTERGAARD FRANDSEN SA (CH) | 2011-10-13 | — | — | WO | claimed |
| WO-2011124228-A1 | A BIOCIDAL POLYOLEFIN YARN WITH 3-12 FILAMENTS | VESTERGAARD FRANDSEN SA (CH) | 2011-10-13 | — | — | WO | claimed |
| US-20250249024-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER | THE UNIVERSITY OF CHICAGO (US) | 2025-08-07 | — | — | US | disclosed |
| US-20250154597-A1 | TRANSCRIPTIONAL REPROGRAMMING DIFFERENTIATES ACTIVE FROM INACTIVE ESR1 FUSIONS IN ENDOCRINE THERAPY-REFRACTORY METASTATIC BREAST CANCER | BAYLOR COLLEGE OF MEDICINE (US) | 2025-05-15 | — | — | US | disclosed |
| US-12280066-B2 | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240355476-A1 | METHODS AND COMPOSITIONS RELATED TO TRIPLE-NEGATIVE BREAST CANCER | THE UNIVERSITY OF CHICAGO (US) | 2024-10-24 | — | — | US | disclosed |
| EP-4416307-A2 | TRANSCRIPTIONAL REPROGRAMMING DIFFERENTIATES ACTIVE FROM INACTIVE ESR1 FUSIONS IN ENDOCRINE THERAPY-REFRACTORY METASTATIC BREAST CANCER | Baylor College of Medicine (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-3912626-B1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISM AND PROSTATE CANCER | UNIV CHICAGO (US) | 2024-08-21 | — | — | EP | disclosed |
| US-12062444-B2 | Methods and compositions related to triple-negative breast cancer | THE UNIVERSITY OF CHICAGO (US) | 2024-08-13 | — | — | US | disclosed |
| US-20240148754-A1 | METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCER | THE UNIVERSITY OF CHICAGO | 2024-05-09 | — | — | US | disclosed |
| US-11883417-B2 | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer | THE UNIVERSITY OF CHICAGO (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2007071440-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
| WO-2007057457-A2 | NEUROENDOCRINE TUMOR TREATMENT USING MTOR INHIBITORS | NOVARTIS AG (CH) | 2007-05-24 | — | — | WO | disclosed |
| EP-1230238-B1 | PROCESS FOR THE PREPARATION OF FUMAGILLIN | SANOFI AVENTIS (FR) | 2007-05-02 | — | — | EP | disclosed |
| US-6521764-B1 | Stable Fumagillin dicyclohexylamine salt used in veterinary medicine is reacted with an organic acid in alcoholic medium to free the salt | SANOFI-SYNTHELABO (FR) | 2003-02-18 | — | — | US | disclosed |
| EP-1230238-A2 | PROCESS FOR THE PREPARATION OF FUMAGILLIN | Sanofi-Aventis (FR) | 2002-08-14 | — | — | EP | disclosed |
| WO-2000076994-A2 | PROCESS FOR THE PREPARATION OF FUMAGILLIN | SANOFI-SYNTHELABO (FR) | 2000-12-21 | — | — | WO | disclosed |
| US-5900431-A | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections | SANOFI (FR) | 1999-05-04 | — | — | US | disclosed |
| WO-1994019946-A1 | TREATMENT OF MICROSPORIDIAL AND ACANTHAMOEBA KERATOCONJUNCTIVITIS WITH TOPICAL FUMAGILLIN | EMORY UNIVERSITY (US) | 1994-09-15 | — | — | WO | disclosed |